ライフサイエンスコーパス: epoetin alfa

1 a heavily glycosylated protein therapeutic (Epoetin Alfa).

2 fusion and recombinant human erythropoietin (epoetin alfa).

3 eable with recombinant human erythropoietin (epoetin alfa).

4 948 to 3831 during treatment with GM-CSF +/- epoetin alfa.

5 o define the optimal doses and schedules for epoetin alfa.

6 : 182 (50%) to luspatercept and 181 (50%) to epoetin alfa.

7 ith DD-CKD, with an AE profile comparable to epoetin alfa.

8 Hb levels increased from baseline with epoetin alfa.

9 nt is somewhat greater with continued weekly epoetin alfa.

10 which placebo patients were crossed over to epoetin alfa.

11 bel phase during which all patients received epoetin alfa.

12 23 to 28% of these patients were prescribed epoetin alfa.

13 ed hazards ratio of 1.309 (P =.052) favoring epoetin alfa.

14 AKT activation were similar for CNTO 530 and epoetin-alfa.

15 Patients received epoetin alfa 10,000 U three times weekly, which could be

16 design, the single-dose pharmacokinetics of Epoetin alfa (100 U/kg) and an equivalent peptide mass o

17 eekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 addition

18 tarting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n =

19 Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be

20 io, to either GM-CSF (0.3-5.0 microg/kg.d) + epoetin alfa (150 IU/kg 3 times/wk) or GM-CSF (0.3-5.0 m

21 ed to receive luspatercept (178 patients) or epoetin alfa (178 patients), comprising 198 (56%) men an

22 g luspatercept (42 weeks [IQR 20-73]) versus epoetin alfa (27 weeks [19-55]).

23 worth further exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative biologic expla

24 t between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI,

25 Patients received epoetin alfa 40,000 U once weekly, which could be increa

26 enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by e

27 After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be admini

28 Epoetin alfa (40,000 U) or placebo was administered week

29 enter, placebo-controlled, clinical trial of epoetin alfa, 40,000 U subcutaneously, once weekly vs. m

30 sly (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120

31 be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56

32 anemic critically ill patients treated with epoetin alfa, all dosing regimens were well tolerated an

33 ts who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neoreco

34 erall tumor response was similar between the epoetin alfa and placebo groups after three chemotherapy

35 Epoetin alfa and placebo groups had similar median overa

36 Epoetin alfa and placebo patients (n = 109 and n = 115,

37 ; P=0.67) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume

38 Percentages of patients in the epoetin alfa and the placebo groups requiring transfusio

39 s transfused during the 12-week study in the epoetin alfa and the placebo groups were 5.9 and 9.5, re

40 Mean Hb increased by 2.2 +/- 1.3 g/dL (epoetin alfa) and by 0.1 +/- 1.0 g/dL (placebo) in the D

41 ers of Eprex, Epogen (another formulation of epoetin alfa), and Neorecormon.

42 Concordantly, epoetin alfa appeared to increase hemoglobin levels and

43 Epoetin alfa appears to have a beneficial impact on pati

44 These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related

45 multiple times and pooling preservative-free epoetin alfa caused this outbreak of bloodstream infecti

46 Epoetin alfa, compared with placebo, significantly decre

47 This study assessed whether epoetin alfa could maintain RBV dose, improve quality of

48 quently can be treated via administration of epoetin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-

49 roxadustat and 0.68 (0.60 to 0.76) g/dl with epoetin alfa, demonstrating noninferiority (least square

50 The pharmacokinetics of epoetin alfa did not predict pharmacodynamic response in

51 t that in newly diagnosed patients with SCLC epoetin alfa does not affect tumor response to chemother

52 The use of epoetin alfa does not reduce the incidence of red-cell t

53 United States with darbepoetin alfa (DA) or epoetin alfa (EA).

54 The results suggest that epoetin alfa effectively improves functional outcomes in

55 safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct E

56 S. liquefaciens was isolated from pooled epoetin alfa, empty vials of epoetin alfa that had been

57 ninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat

58 Epoetin alfa (EPO) robustly induced bone marrow erythrof

59 ight, subcutaneously, once every 3 weeks) or epoetin alfa for at least 24 weeks.

60 fied interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-r

61 showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stim

62 were punctured multiple times, and residual epoetin alfa from multiple vials was pooled and administ

63 the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV

64 ell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo gr

65 red in 4 of 45 (9%) patients in the GM-CSF + epoetin alfa group compared with 1 of 21 (5%) patients w

66 pt group and 48 (31%) of 154 patients in the epoetin alfa group reached the primary endpoint (common

67 oncentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0

68 e interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3%

69 red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% conf

70 147 in the luspatercept group and 154 in the epoetin alfa group) who completed 24 weeks of treatment

71 pt group and 20.3 months (12.7-30.9) for the epoetin alfa group.

72 pt group and 16.9 months (10.1-26.6) for the epoetin alfa group.

73 nd headache; and none (>=3% patients) in the epoetin alfa group.

74 GM-CSF +/- epoetin alfa had no effect on mean platelet count.

75 ving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compar

76 Prescription of epoetin alfa has been associated with increased survival

77 erature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to referen

78 HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were receiving hemodialysis or darb

79 ased haemoglobin were achieved compared with epoetin alfa in ESA-naive patients with lower-risk myelo

80 ective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia

81 ted in patients who switched from placebo to epoetin alfa in the OLP.

82 mulating factor (GM-CSF) and erythropoietin (epoetin alfa) in anemic, neutropenic patients with myelo

83 inical trials have shown that treatment with epoetin alfa increases hemoglobin levels, reduces fatigu

84 Treatment with epoetin alfa is associated with an increase in the incid

85 Epoetin alfa is effective in improving the functional st

86 Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia

87 Epoetin alfa maintained RBV dose and improved QOL and Hb

88 erapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfu

89 s or reactions were associated with doses of epoetin alfa of more than 4000 U (multivariate odds rati

90 To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted i

91 olled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic

92 led trial (N93-004) evaluated the effects of epoetin alfa on tumor response to chemotherapy and survi

93 domly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered wit

94 a mouse model, single-dose CNTO 530 (unlike epoetin-alfa or darbepoietin-alfa) bolstered red cell pr

95 erythroblasts at frequencies multifold above epoetin-alfa or darbepoietin-alfa.

96 In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in an

97 showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression

98 Fewer epoetin alfa patients than placebo patients required tra

99 s maintained in the prechemotherapy range in epoetin alfa patients, but decreased substantially in pl

100 roxadustat three times weekly or parenteral epoetin alfa per local clinic practice.

101 ajority of these patients received Eprex, an epoetin alfa product marketed exclusively outside the Un

102 In conclusion, epoetin alfa provided clinically significant HRQL improv

103 lodysplastic syndromes (six [3%]); and among epoetin alfa recipients (n=179) were anaemia (14 [8%]),

104 ine [5%] luspatercept recipients and 13 [7%] epoetin alfa recipients) and COVID-19 (eight [4%] luspat

105 ht [4%] luspatercept recipients and ten [6%] epoetin alfa recipients).

106 raged over weeks 28-52 for roxadustat versus epoetin alfa, regardless of rescue therapy use, tested f

107 One of six dosing epoetin alfa regimens for 15 days, as follows: 40,000 IU

108 .6% with roxadustat and 84.5% and 57.5% with epoetin alfa, respectively.

109 inical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well a

110 Treatment with epoetin alfa resulted in significant increases in hemogl

111 Epoetin alfa safely and effectively ameliorates anemia a

112 Epoetin alfa significantly improved HgB and reduced tran

113 ients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by baseline red blood cell tran

114 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-w

115 were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 1

116 were associated with higher median doses of epoetin alfa than the 188 other sessions (6500 vs. 4000

117 ted from pooled epoetin alfa, empty vials of epoetin alfa that had been pooled, antibacterial soap, a

118 ety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke

119 As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in eit

120 and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are sim

121 mmunity-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decrea

122 the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases i

123 Epoetin alfa therapy was also associated with a signific

124 Epoetin alfa therapy was associated with improved qualit

125 30, 1,047 patients completed all 4 months of epoetin alfa therapy.

126 The administration of the ESA epoetin alfa to critically ill trauma patients has been

127 Administration of epoetin alfa to older adult patients with heart failure

128 Addition of epoetin alfa to radical radiotherapy did not affect surv

129 he authors aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients i

130 ized, double-blind clinical trial evaluating epoetin alfa versus placebo in anemic cancer patients.

131 igue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.

132 were maintained in 88% of patients receiving epoetin alfa vs. 60% of patients receiving placebo (P <

133 Epoetin alfa was administered subcutaneously once a week

134 In addition, epoetin alfa was associated with a significant increase

135 As compared with placebo, epoetin alfa was associated with a significant increase

136 Epoetin alfa was associated with significant increases i

137 After the practice of pooling epoetin alfa was discontinued and the contaminated soap

138 Once-weekly epoetin alfa was well tolerated, with most adverse event

139 Epoetin alfa was well tolerated.

140 Epoetin alfa was well tolerated; the most common adverse

141 odysplastic syndromes, and syncope; and with epoetin alfa were anaemia, pneumonia, neutropenia, hyper

142 that preservative-free, single-use vials of epoetin alfa were punctured multiple times, and residual

143 Patients receiving epoetin alfa who had the greatest Hb increases from rand

144 ical improvement with luspatercept than with epoetin alfa, with benefits observed across patient subg

145 or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarc

146 sized that treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricula